128 related articles for article (PubMed ID: 18184406)
21. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
22. Augmenting the activity of antifungal agents against aspergilli using structural analogues of benzoic acid as chemosensitizing agents.
Kim JH; Campbell BC; Mahoney N; Chan KL; Molyneux RJ; Balajee A
Fungal Biol; 2010 Oct; 114(10):817-24. PubMed ID: 20943191
[TBL] [Abstract][Full Text] [Related]
23. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.
Monforte V; Ussetti P; López R; Gavaldà J; Bravo C; de Pablo A; Pou L; Pahissa A; Morell F; Román A
J Heart Lung Transplant; 2009 Feb; 28(2):170-5. PubMed ID: 19201343
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
Manetti F; Castagnolo D; Raffi F; Zizzari AT; Rajamäki S; D'Arezzo S; Visca P; Cona A; Fracasso ME; Doria D; Posteraro B; Sanguinetti M; Fadda G; Botta M
J Med Chem; 2009 Dec; 52(23):7376-9. PubMed ID: 19650630
[TBL] [Abstract][Full Text] [Related]
25. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Kaneko M; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
J Antimicrob Chemother; 2008 Feb; 61(2):411-6. PubMed ID: 18055488
[TBL] [Abstract][Full Text] [Related]
26. Drug-drug interactions with systemic antifungals in clinical practice.
Depont F; Vargas F; Dutronc H; Giauque E; Ragnaud JM; Galpérine T; Abouelfath A; Valentino R; Dupon M; Hébert G; Moore N
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1227-33. PubMed ID: 17879355
[TBL] [Abstract][Full Text] [Related]
27. In vitro effect of antifungal drugs on pathogenic Naegleria spp.
Tiewcharoen S; Junnu V; Chinabut P
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):38-41. PubMed ID: 12118457
[TBL] [Abstract][Full Text] [Related]
28. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.
Oakley KL; Moore CB; Denning DW
Antimicrob Agents Chemother; 1999 May; 43(5):1264-6. PubMed ID: 10223948
[TBL] [Abstract][Full Text] [Related]
29. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
Chryssanthou E; Loebig A; Sjölin J
J Antimicrob Chemother; 2008 Jun; 61(6):1309-11. PubMed ID: 18367461
[TBL] [Abstract][Full Text] [Related]
30. Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus.
Rodrigues AG; Araujo R; Pina-Vaz C
Int J Antimicrob Agents; 2006 Apr; 27(4):339-43. PubMed ID: 16527460
[TBL] [Abstract][Full Text] [Related]
31. Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus.
Simitsopoulou M; Roilides E; Georgiadou E; Paliogianni F; Walsh TJ
Med Mycol; 2011 Feb; 49(2):176-85. PubMed ID: 20807031
[TBL] [Abstract][Full Text] [Related]
32. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
33. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
34. Screening method to identify inhibitors of siderophore biosynthesis in the opportunistic fungal pathogen, Aspergillus fumigatus.
Pinto LJ; Moore MM
Lett Appl Microbiol; 2009 Jul; 49(1):8-13. PubMed ID: 19453952
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of DNA, (1-3)-beta-d-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with Aspergillus terreus.
Ahmad S; Khan ZU; Theyyathel AM
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):165-71. PubMed ID: 17574786
[TBL] [Abstract][Full Text] [Related]
36. Activity of pradimicin BMS-181184 against Aspergillus spp.
Oakley KL; Moore CB; Denning DW
Int J Antimicrob Agents; 1999 Aug; 12(3):267-9. PubMed ID: 10461847
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
Ho KM; Duff O; Chambers D; Murray R
Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
[TBL] [Abstract][Full Text] [Related]
38. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
39. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis.
Kontoyiannis DP
Clin Infect Dis; 2002 May; 34(9):1281-3; author reply 1283. PubMed ID: 11941561
[No Abstract] [Full Text] [Related]
40. Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis.
Hidalgo A; Parody R; Martino R; Sánchez F; Franquet T; Giménez A; Blancas C
Eur J Radiol; 2009 Jul; 71(1):55-60. PubMed ID: 18468830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
